TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, announced last week that within the last 60 days the company secured an additional $600,000 in equity funding, bringing the total for the last six months of 2009 to over $1,000,000. The recent investors acquired $.80 units with each unit comprised of one share and one warrant exercisable at $1.20 for a period of 5 years.

The recent restructuring taken place at TapImmune has provided a more secure framework from which to pursue investment and industry partnerships. The company is dedicated to working diligently to secure additional funding and to move its product development and business forward.

Let us hear your thoughts: TapImmune, Inc. Message Board